Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada

Table 1

Model inputs.

Model inputs	Mean	Low	High	Data source
Monthly event probabilities in the study population
Probability of exacerbation in the 1st month	0.257	0.206	0.308	[7, 8]
Probability of exacerbation after the 1st month	0.059	0.047	0.071	[7, 8]
Probability of dying for severe exacerbation	0.110	0.088	0.132	[9, 10]
Probability of dying for no or moderate exacerbation	0.010	0.008	0.012	[9, 11–13]
Aerobika® device effect on exacerbations
Relative risk of exacerbation in the 1st month	0.720	0.576	0.864	[7, 8]
Relative risk of exacerbation after the 1st month	1.000	0.800	1.200	[8]
Distribution of exacerbations
Severe exacerbation if using Aerobika® device	0.691	0.553	0.830	[8]
Severe exacerbation if not using Aerobika® device	0.706	0.565	0.848	[8]
Healthcare cost per patient per month
Severe exacerbation	$13,119	$10,495	$15,743	[14]
Moderate exacerbation	$456	$365	$547	[14]
No exacerbation	$65	$52	$78	[1, 8, 14]
Cost of Aerobika® device per patient per year	$90			[15]
QALY
Utility score for people with COPD	0.897	0.718	1.000	[13, 16]
Utility decrement if severe exacerbation (per month)	0.504	0.403	0.605	[16, 17]
Utility decrement if moderate exacerbation (per month)	0.120	0.096	0.144	[16, 17]

Per year.